Suppr超能文献

利妥昔单抗剂量对 ABO 不相容活体肾移植诱导治疗的影响:一项网络荟萃分析。

Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis.

机构信息

Division of Nephrology, Department of Internal Medicine, Leesin Hemodialysis and Intervention Clinic, Busan.

Division of Nephrology and Hypertension, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea.

出版信息

Medicine (Baltimore). 2021 Mar 12;100(10):e24853. doi: 10.1097/MD.0000000000024853.

Abstract

BACKGROUND

Rituximab is an induction immunosuppressant essential for ABO-incompatible kidney transplantation (ABOi KT). However, studies on its dosing, which differs among countries and transplant centers, are lacking. Therefore, we retrospectively investigated the effectiveness of the induction dose of rituximab against patient mortality, graft failure, and adverse events.

METHODS

We included the studies referring to at least 2 of eligible induction doses (200 mg, 200-500 mg, or 500 mg) of rituximab during ABOi KT and relevant outcomes such as patient survival, graft failure, and bacterial and viral infections. We performed direct and indirect network meta-analyses using Bayesian models and ranked different rituximab doses using generation mixed treatment comparison. Publications were retrieved using CENTRAL, MEDLINE, EMBASE, and Science Citation Index Expanded databases from 1970 to February 2020 and analyzed. The GRADE of network meta-analysis approach specified 4 levels of certainty for a given result: high, moderate, low, and very low.

RESULTS

Among the 4256 patients from 21 trials, glomerular filtration rate, graft loss, antibody-mediated rejection, T-cell mediated rejection, fungal infection, bacterial infection, and CMV infection did not differ among ABOi groups treated with different rituximab doses. The effect on mortality was significantly higher in rituximab 200 to 500 mg, and rituximab 500 mg groups (odds ratios [OR] 3.5, 95% CrI: 1.3-9.8, and OR 3.0, 95% CrI 1.1-9.8), but not in rituximab 20 mg group (OR 0.45, 95% CrI 0.036-2.5). The incidence of BK virus was significantly lower in the rituximab 200-mg group than in the other groups.

DISCUSSION

In ABO-incompatible kidney transplantation, low-dose rituximab is more efficacious than higher doses and reduces serious infection risks. Additional randomized controlled trials might be needed to confirm these findings due to small sample size.

摘要

背景

利妥昔单抗是 ABO 不相容肾移植(ABOi KT)中必不可少的诱导免疫抑制剂。然而,由于各国和移植中心的剂量不同,缺乏相关研究。因此,我们回顾性研究了利妥昔单抗诱导剂量对患者死亡率、移植物失败和不良事件的影响。

方法

我们纳入了至少涉及 2 种利妥昔单抗诱导剂量(200mg、200-500mg 或 500mg)的研究,并观察了患者生存率、移植物失败以及细菌和病毒感染等相关结局。我们使用贝叶斯模型进行了直接和间接网络荟萃分析,并使用生成混合治疗比较对不同的利妥昔单抗剂量进行了排名。使用 CENTRAL、MEDLINE、EMBASE 和科学引文索引扩展数据库从 1970 年至 2020 年 2 月检索文献,并进行了分析。网络荟萃分析方法的 GRADE 为特定结果指定了 4 个级别的确定性:高、中、低和极低。

结果

在 21 项试验的 4256 名患者中,肾小球滤过率、移植物丢失、抗体介导的排斥反应、T 细胞介导的排斥反应、真菌感染、细菌感染和 CMV 感染在接受不同利妥昔单抗剂量治疗的 ABOi 组之间没有差异。利妥昔单抗 200-500mg 和利妥昔单抗 500mg 组的死亡率显著升高(比值比[OR] 3.5,95%可信区间[CrI]:1.3-9.8,和 OR 3.0,95% CrI 1.1-9.8),但利妥昔单抗 20mg 组无显著差异(OR 0.45,95% CrI 0.036-2.5)。利妥昔单抗 200mg 组的 BK 病毒发生率显著低于其他组。

讨论

在 ABO 不相容肾移植中,低剂量利妥昔单抗比高剂量更有效,并降低严重感染风险。由于样本量小,可能需要进一步的随机对照试验来证实这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f81/7969271/b2ad74604ff9/medi-100-e24853-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验